Kaempferia parviflora Ethanol Extract, a Peroxisome Proliferator-Activated Receptor Ligand-binding Agonist, Improves Glucose Tolerance and Suppresses Fat Accumulation in Diabetic NSY Mice

被引:20
|
作者
Ochiai, Masaru [1 ]
Takeuchi, Toshiki [2 ]
Nozaki, Tsutomu [3 ]
Ishihara, Ken-o [3 ]
Matsuo, Tatsuhiro [2 ]
机构
[1] Kitasato Univ, Sch Vet Med, 23-35-1 Higashi, Towada, Aomori 0348628, Japan
[2] Kagawa Univ, Fac Agr, Kita Ku, 2393 Ikenobe, Miki, Kagawa 7610795, Japan
[3] BHN Co Ltd, Chiyoda Ku, 1-16 Kandanishiki, Tokyo 1010054, Japan
关键词
fat accumulation; glucose tolerance; Kaempferia parviflora; methoxy flavone; PPAR; ETHYL-ACETATE EXTRACT; TISSUE DISTRIBUTION; INSULIN-RESISTANCE; PANCREATIC LIPASE; PPAR-GAMMA; 5,7-DIMETHOXYFLAVONE; MOUSE; RAT; POLYMETHOXYFLAVONOIDS; PHARMACOKINETICS;
D O I
10.1111/1750-3841.14437
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study assessed the effect of Kaempferia parviflora, also known as black ginger (BG), and its ethanol extract (BGE) on peroxisome proliferator-activated receptor (PPAR) agonistic activity, glucose tolerance, fat accumulation, and lipids-induced hypertriglyceridemia in mice. PPAR ligand-binding capacity in vitro and polymethoxy flavone contents were highly observed in organic solvent extracts. In an animal experiment A, male diabetic Nagoya-Shibata-Yasuda mice were divided into five dietary groups and fed each diet for 8 weeks: AIN-93G diet (low-fat [LF] diet), high-fat (HF) diet, HF diet supplemented with 1% BG, HF diet supplemented with 0.19% BGE, and HF diet supplemented with pioglitazone (PPAR agonist, 3 mg/kg/day) as a PPAR agonistic positive control. As determined from glucose and insulin tolerance tests, plasma glucose levels were improved in the BG and BGE groups. The BGE extract suppressed fat accumulation in adipose tissues, liver, and muscles without changing the plasma adiponectin level. In an animal experiment B, in order to investigate the effect of BG and BGE on lipid-induced hypertriglyceridemia, male ddY mice were divided into three test groups: control, BG-administered group (500 mg/kg), and BGE-administered group (100 mg/kg). The plasma triacylglycerol level was not different among the groups during the lipids administration test. These results conclude that the BGE extract containing several kinds of polymethoxy flavones showed PPAR ligand-binding capacity in vitro and prevented obesity and insulin resistance independent of adiponectin secretion in mice.
引用
收藏
页码:339 / 348
页数:10
相关论文
共 50 条
  • [21] L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ -: The role of Cys313 in ligand binding
    Elbrecht, A
    Chen, YL
    Adams, A
    Berger, J
    Griffin, P
    Klatt, T
    Zhang, B
    Menke, J
    Zhou, GC
    Smith, RG
    Moller, DE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) : 7913 - 7922
  • [22] Fenofibrate, a Peroxisome Proliferator-Activated Receptor α Agonist, Improves Hepatic Microcirculatory Patency and Oxygen Availability in a High-Fat-Diet-Induced Fatty Liver in Mice
    Kondo, Kazunari
    Sugioka, Tadao
    Tsukada, Kosuke
    Aizawa, Michiyoshi
    Takizawa, Masayuki
    Shimizu, Kenji
    Morimoto, Masaya
    Suematsu, Makoto
    Goda, Nobuhito
    OXYGEN TRANSPORT TO TISSUE XXXI, 2010, 662 : 77 - 82
  • [23] Insights into the mechanism of partial agonism -: Crystal structures of the peroxisome proliferator-activated receptor γ ligand-binding domain in the complex with two enantiomeric ligands
    Pochetti, Giorgio
    Godio, Cristina
    Mitro, Nico
    Caruso, Donatella
    Galmozzi, Andrea
    Scurati, Samuele
    Loiodice, Fulvio
    Fracchiolla, Giuseppe
    Tortorella, Paolo
    Laghezza, Antonio
    Lavecchia, Antonio
    Novellino, Ettore
    Mazza, Fernando
    Crestani, Maurizio
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (23) : 17314 - 17324
  • [24] Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis
    Larter, Claire Z.
    Yeh, Matthew M.
    Van Rooyen, Derrick M.
    Brooling, John
    Ghatora, Kamaljit
    Farrell, Geoffrey C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (02) : 341 - 350
  • [25] Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease
    Yu, J.
    Zhang, Z.
    Li, Z.
    Feng, X.
    He, L.
    Liu, S.
    Mao, J.
    Wang, G.
    Wang, X.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (01) : 86 - 94
  • [26] A Selective Peroxisome Proliferator-Activated Receptor α Agonist, CP-900691, Improves Plasma Lipids, Lipoproteins, and Glycemic Control in Diabetic Monkeys
    Wagner, Janice D.
    Shadoan, Melanie K.
    Zhang, Li
    Ward, Gina M.
    Royer, Lori J.
    Kavanagh, Kylie
    Francone, Omar L.
    Auerbach, Bruce J.
    Harwood, H. James, Jr.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 333 (03): : 844 - 853
  • [27] A highly selective peroxisome proliferator-activated receptor α (PPARα) agonist, NS-220, decreases plasma glucose levels and ameliorates lipoprotein profiles in diabetic mice
    Kuwabara, K
    Murakami, K
    Todo, M
    Yano, J
    CIRCULATION, 2002, 106 (19) : 210 - 210
  • [28] Peroxisome proliferator-activated receptor (PPAR) α or γ does not change ischemic tolerance in hearts from type 2 diabetic mice.
    Aasum, E
    Carley, A
    Larsen, TS
    Severson, DL
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2002, 34 (06) : A3 - A3
  • [29] Amino acid residues in both the DNA-binding and ligand-binding domains influence transcriptional activity of the human peroxisome proliferator-activated receptor alpha
    Myers, KA
    Lambe, KG
    Aldridge, TC
    Macdonald, N
    Tugwood, JD
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 239 (02) : 522 - 526
  • [30] Peroxisome proliferator-activated receptor-α,γ-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice
    Verreth, W
    Ganame, J
    Mertens, A
    Bernar, H
    Herregods, MC
    Holvoet, P
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (04) : 922 - 928